In July 2008, LeukemiaTexas awarded three new research grants:
- $150,000 grant to The University of Texas MD Anderson Cancer Center for Overcoming stromal-mediated drug resistance cells: the role of fatty acid metabolism in the Warburg effect - Ismael J. Samudio, Ph.D., Principal Investigator. This is a Young Investigator Award to Dr. Samudio.
- $150,000 grant to UT Health Science Center at San Antonio for Aurora A: A Novel Therapeutic Target for Imatinib, Desatinib, Nilotininb and Bosutinib-Resistant Chronic Myeloid Leukemia and Ph Acute Lymphoblastic Leukemia - Jennifer Carew, Ph.D. and Frank Giles, M.D., Principal Investigators. This is a Young Investigator Award to Dr. Carew.
- $150,000 grant to The University of Texas Southwestern Medical Center for Development of a novel targeted therapy for acute and chronic leukemias - Pier Paolo Scaglioni, Ph.D., Principal Investigator.
Since 2002, LeukemiaTexas has also awarded grants for the following research:
- $191,530 grant to Baylor Research Institute for Development of a Cancer Cell Vaccine for Treatment of Multiple Myeloma and Plasma Cell Leukemia. This new study utilized translation studies to explore developing a cancer cell vaccine as a new treatment for Plasma Cell Leukemia and Multiple Myeloma.
- $300,000 grant to The University of Texas Southwestern Medical Center for Allodepleted T-Cell Infusions in Patients Receiving Nonmyeloablative Hematopoietic Stem Cell Transplants. This new study gathered allogeneic hematopoietic cell transplantation data and utilized selective allodepletion to decrease graft vs host disease.
- $362,861 grant to Baylor Research Institute for The Effect of HLA Mismatches on the Outcome of Unrelated Donor-Bone Marrow Transplants in the Treatment of Leukemia and Lymphoma. This study has resulted in an improved allogeneic bone marrow transplant process while reducing immunologic complications due to imperfect tissue matching.
- $225,000 grant to The University of Texas Southwestern Medical Center for The Study of Mechanisms of Graft vs Host Disease Using Quantitative Assay of Antigen-Specific T Cells. This study applied to all types of leukemia and has produced a completely new and improved treatment methodology for allogeneic stem cell transplantations.